Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)

A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase. The investigator plans to evaluate grade 1 or higher rectal bleeding occurring within 3 years in patients who have received low -fractionation curative radiotherapy.

Trial Details

NCT ID
NCT06461819
Phase
PHASE2
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Prostate cancer patients confirmed histopathologically within 6 months prior to study enrollment
  • Low-risk and medium- risk groups in terms of risk Prostate cancer patients (primary stage T2c or less, Grade group 3 or less, If PSA is less than 2…
  • Adults over 20 years of age
  • Whole body performance ECOG 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →